Clinical Trial Update: Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial assessing safety and efficacy of an anti-BCMA/FcRL5 CAR-T cell therapy for relapsed/refractory multiple myeloma. The study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-BCMA/FcRL5 CAR-T cell therapy (CAR-T cell therapy targeting BCMA and FcRL5)

Snippet

Sponsor: Xuzhou Medical University | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: RECRUITING